NCT03694262 2026-04-13
EndoBARR
Medical College of Wisconsin
Phase 2 Completed
Clinical Trials
12 trialsNCT02873962 2026-04-01
A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT03617679 2026-03-24
Rucaparib vs Placebo Maintenance Therapy in Metastatic and Recurrent Endometrial Cancer
University of Colorado, Denver
Phase 2 Completed
NCT04539327 2026-03-18
Analysis of the Clinical Experience With Rucaparib in the Rucaparib Access Program (RAP) in Spain - A GEICO Study
Grupo Español de Investigación en Cáncer de Ovario
Completed
NCT03552471 2025-02-13
Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Ohio State University Comprehensive Cancer Center
Phase 1 Completed
NCT04826198 2024-12-05
REVOCAN
Gustave Roussy, Cancer Campus, Grand Paris
Phase 1/2 Terminated
NCT04227522 2024-11-15
MAMOC
North Eastern German Society of Gynaecological Oncology
Phase 3 Completed
NCT03476798 2024-02-15
Clovis-001
University of Oklahoma
Phase 2 Completed
NCT03462212 2021-08-27
MITO25
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Phase 1/2 Unknown
NCT03572478 2021-03-09
Rucaparib and Nivolumab in Patients With Prostate or Endometrial Cancer
University of Chicago
Phase 1/2 Terminated
NCT03795272 2019-11-01
MaRuC
Nordic Society of Gynaecological Oncology - Clinical Trials Unit
Phase 2 Withdrawn
NCT00664781 2016-05-24
Rucaparib(CO-338;Formally Called AG-014699 or PF-0136738) in Treating Patients With Locally Advanced or Metastatic Breast Cancer or Advanced Ovarian Cancer
Cancer Research UK
Phase 2 Completed